Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc

@inproceedings{Bsteh2017SevereEN,
  title={Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc},
  author={Gabriel Bsteh and Michael Auer and Sarah Iglseder and Lisa-Maria Walchhofer and Dietmar Langenscheidt and Stefan Koppi and Gabriele Schauer-Maurer and Guenther Stockhammer and Thomas F H Berger},
  booktitle={Neurology(R) neuroimmunology & neuroinflammation},
  year={2017}
}
Case report. A 55-year-old Caucasian HIV-negative man diagnosed with relapsing-remitting MS in 2013 and an Expanded Disability Status Scale (EDSS) score of 2.0 had received 20 infusions of natalizumab over 21 months without a history of prior immunotherapy. John Cunningham–virus (JCV) antibodies were positive at the initiation of treatment (index: 0.4). Natalizumab was then discontinued because of an increase of anti-JCV antibody index (2.6) and switched to fingolimod following a 2-month… CONTINUE READING